Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Sep 28, 2021 9:57am
94 Views
Post# 33929977

RE:RE:RE:RE:RE:RE:Calling a special meeting

RE:RE:RE:RE:RE:RE:Calling a special meeting

I am as strongly against the moth-balling of the NASH program as I am against them making a terrible decision. Giving the future of that program is contingent on ongoing processes and future milestones that nobody can predict it just makes zero sense to tie down management at this point.

Basically this comes down to whether you think management (and the board) have the best interest of the company. Whether you back management to manage. You basically want to leash management, I don't think the response from them will be all that positive.


jeffm34 wrote:

I can't speak for the major shareholders. My own personal views are that the NASH program should not proceed without a partner, no matter how creative they get in raising funds to do so. If there is a decent chance of success, other companies will be more than willing to validate the program by putting up their own cash. If no one steps forward it would be irresponsible of management to continue given no other company deems the program worthwhile. 

 

palinc2000 wrote:

 

What would you want to make
Clear?
 

 

jeffm34 wrote:

 

I think given their track record there is cause for concern. If I were a major shareholder, I would want to make my views very clear to management at this point. 

 

palinc2000 wrote:

 

I respectfully disagree 100%....Waste of time and energy and money 


 

 




<< Previous
Bullboard Posts
Next >>